

## A phase 1/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB)

MP Marinkovich<sup>1, 4\*</sup>, A Lane<sup>1,3</sup>, K Sridhar<sup>1</sup>, D Keene<sup>2</sup>, A Malyala<sup>3</sup>, M Spellman<sup>3</sup>, J Maslowski<sup>3</sup>

<sup>1</sup>Stanford University School of Medicine, Stanford, CA <sup>2</sup>Shriners Hospital for Children, Portland, OR <sup>3</sup>Castle Creek Pharma, Exton, PA, USA. <sup>4</sup>Veterans Affairs Medical Center, Palo Alto, Stanford, CA  
\*mmp@stanford.edu

### INTRODUCTION & BACKGROUND

Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited genetic skin blistering disease caused by mutations in the COL7A1 gene encoding type VII collagen (C7) that results in dermal-epidermal separation. Current therapy for RDEB is limited to palliative wound care as there are no curative treatments and no approved drugs for RDEB. We report the results of the ongoing Phase 1/2 clinical trial of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts (FCX-007) for the treatment of RDEB wounds (NCT02810951). The primary objective of this study is to evaluate the safety of intradermal injection of FCX-007. Secondary objectives are to evaluate clinical efficacy via percent wound healing compared to baseline and evaluate pharmacology via immunofluorescence (IF) and immunoelectron microscopy (IEM).

### DEMOGRAPHICS

**Table 1. Clinical Characteristics of Subjects**

Subject #	101	102	103	104	105	106
Age at enrollment	26	21	33	38	33	9
Sex	M	M	M	F	M	M
COL7A1 Mutation 1	5048_5051 dup (GAAA) (exon 54)	5048_5051 dup (GAAA) (exon 54)	6527dupC (exon 80)	356_357 delCA	8440 C>T (homozygous)	1573 C>T
COL7A1 Mutation 2	90delC (exon 2)	90delC (exon 2)	7485 + 5 G>A (intron 98)	2017G>T	8440 C>T (homozygous)	6527dupC
COL7 Expression (IF)	Negative	Negative	Negative	Negative	Negative	Negative
COL7 Expression (WB)	NC-1 positive	NC-1 positive	NC-1 positive	NC-1 negative (null)	NC-1 positive	NC-1 positive
Electron Microscopy	no AF/sublamina densa split	no AF/sublamina densa split	no AF/sublamina densa split	no AF/sublamina densa split	no mature AF	no AF/sublamina densa split
COL7 Autoantibodies	Negative	Negative	Negative	Negative	Negative	Negative
History of SCC	No	No	No	Yes	Yes	No

AF anchoring fibrils; IF immunofluorescence; NC-1 non-collagenous-1; SCC squamous cell carcinoma; WB Western blot

### RESULTS

#### Safety

Interim data from the six subjects show that FCX-007 was well tolerated up to 52 weeks post-administration with no antibody response to C7 detected after initial or repeat administration. No replication-competent lentivirus (RCL) and no C7 antibody responses have been noted in serum samples from subjects, including one subject with a negative NC-1 genotype.

Three subjects treated with FCX-007 had serious adverse events (SAE). Two subjects had SAEs of squamous cell carcinoma (SCC) progression (not at the sites of FCX-007 treatment) with one subject's SAE resulting in fatality. The SAEs of SCC progression were deemed unrelated to the investigational product. One subject had an SAE of flu that resulted in hospitalization approximately one-month post-FCX-007 treatment that was deemed unrelated to the investigational product.

The injection procedure was well tolerated by all subjects. Erythema and injection site discoloration were reported and deemed possibly related and related, respectively, to the investigational product. These resolved quickly except in one subject with resolution within 1 week.

#### Efficacy

**Table 2. Treated Wound Healing Data**


	Observed % Healing 4 Weeks (Number of Wounds)	Observed % Healing 12 Weeks (Number of Wounds)	Observed % Healing 25 Weeks (Number of Wounds)	Observed % Healing 52 Weeks (Number of Wounds)
≥50% Wound Healing	80% (8/10)	90% (9/10)	75% (3/4)	83% (5/6)
≥75% Wound Healing	70% (7/10)	80% (8/10)	75% (3/4)	67% (4/6)
100% Wound Closure	20% (2/10)	60% (6/10)	50% (2/4)	33% (2/6)

**Table 3. Untreated Wound Healing Data**

	Observed % Healing 4 Weeks (Number of Wounds)	Observed % Healing 12 Weeks (Number of Wounds)	Observed % Healing 25 Weeks (Number of Wounds)	Observed % Healing 52 Weeks (Number of Wounds)
≥50% Wound Healing	20% (2/10)	44% (4/9)	50% (2/4)	33% (2/6)
≥75% Wound Healing	10% (1/10)	11% (1/9)	0% (0/4)	16% (1/6)
100% Wound Closure	0% (0/10)	0% (0/9)	0% (0/4)	16% (1/6)

Digital images captured and wound tracings performed. Skin tattoos and transparent overlays were used as landmarks. Best matched untreated wound was also monitored in conjunction with each treated wound on the same patient. Wounds were assessed for percent wound healing compared to baseline. Week 52 visit has not occurred for subject 0106. The number of wounds observed for wound healing decreased over time due to subjects unable to attend clinic visits and image capture technical issues. Vector presence was detected by PCR 25 weeks after injection into intact and wound treated skin.

**Figure 1. Gene-corrected Autologous Fibroblasts (FCX-007)**



(A) Fibroblasts isolated from RDEB patient skin biopsy. (B) Fibroblasts expanded and transduced with SIN lentiviral vector encoding COL7A1. (C) Genetically-corrected autologous fibroblasts (FCX-007) ready for intradermal administration.

### METHODS

Six subjects, five adults and one child, with severe generalized RDEB (ages 9 to 38 at age of enrollment) were dosed with FCX-007. The subjects carried various COL7A1 mutations resulting in undetectable C7 expression by immunofluorescence microscopy (IF) and a lack of anchoring fibrils (AF) by electron microscopy (EM) (Table 1). The therapy was administered in the margins of and across targeted chronic wounds, ranging in size from 4.3 to 34.1 cm<sup>2</sup>, as well as in separate intact skin sites. Persistent non-healing wounds were targeted to assess efficacy of wound healing (categorical scale: 0%, 1-9%, 10-24%, 25-49%, 50-74%, 75-89%, 90-99% and 100% healed) and pharmacology via IF and IEM. All six subjects received a single treatment session at baseline. Four subjects received a second treatment session at 52, 25, 12, and 4 weeks post-baseline administration; subjects 0102, 0103, 0105 and 0106, respectively.


**Figure 2. Subject 0106 Treated Wound**



**Figure 3. Subject 0106 Untreated Control Wound**




**Figure 4. C7 Expression Following Injection FCX-007**



Linear C7 protein was detected by IF at the dermal-epidermal junction at 25 weeks and 52 weeks following injection into skin of subject 0101, and at 12 and 25 weeks in subject 0103. At 25 weeks, a second injection of FCX-007 was performed on patient 3, and at 32 weeks, linear robust C7 expression was noted at the reinjection site.

**Figure 5. C7 Ultrastructural Localization**



IEM analysis at week 25 following injection of FCX-007 into intact skin was performed using LH24 mAb. Note punctate C7 labeling below BMZ opposite hemidesmosomes; arrows pointing to linear projections of anchoring fibrils (AFs). (Right panel) Higher magnification IEM analysis.

### CONCLUSIONS

In this interim data set, FCX-007 was well tolerated up to 52 weeks post-administration. Injections of both wounded and intact skin were well tolerated without safety issues, including a lack of immune or RCL related events. Positive wound healing trends and pharmacology signals were observed for up to 52 weeks of testing. These results informed design of the phase 3 DEFI-RDEB study (NCT04213261).